Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT – Get Free Report) saw a significant decline in short interest during the month of October. As of October 30th, there was short interest totaling 11,020,929 shares, a decline of 48.2% from the October 15th total of 21,260,757 shares. Based on an average trading volume of 29,799,680 shares, the days-to-cover ratio is presently 0.4 days. Currently, 13.5% of the shares of the stock are sold short.
Analyst Upgrades and Downgrades
EYPT has been the subject of several recent analyst reports. Citigroup lowered their target price on Eyepoint Pharmaceuticals to $17.00 and set a “buy” rating for the company in a research note on Tuesday, August 18th. Guggenheim cut Eyepoint Pharmaceuticals from a “buy” rating to a “neutral” rating in a research report on Monday, October 19th. HC Wainwright reaffirmed a “neutral” rating on shares of Eyepoint Pharmaceuticals in a research report on Tuesday, October 20th. Laidlaw downgraded shares of Eyepoint Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Tuesday, October 20th. Finally, Weiss Ratings cut shares of Eyepoint Pharmaceuticals from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Friday. Two equities research analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Hold” and a consensus price target of $21.85.
View Our Latest Report on EYPT
Eyepoint Pharmaceuticals Stock Down 3.8%
Shares of EYPT stock traded down $0.01 on Tuesday, reaching $0.30. The stock had a trading volume of 4,575,241 shares, compared to its average volume of 3,706,404. The firm’s 50-day moving average is $2.24 and its two-hundred day moving average is $10.17. Eyepoint Pharmaceuticals has a 12 month low of $0.28 and a 12 month high of $19.11. The firm has a market capitalization of $25.51 million, a price-to-earnings ratio of -0.07 and a beta of 1.84.
Eyepoint Pharmaceuticals (NASDAQ:EYPT – Get Free Report) last posted its quarterly earnings data on Thursday, November 12th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.93) by ($0.14). Eyepoint Pharmaceuticals had a negative net margin of 13,281.23% and a negative return on equity of 146.17%. The business had revenue of $0.76 million during the quarter, compared to the consensus estimate of $0.23 million. On average, sell-side analysts forecast that Eyepoint Pharmaceuticals will post -3.46 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Eyepoint Pharmaceuticals
Several large investors have recently bought and sold shares of EYPT. Janus Henderson Group PLC lifted its position in shares of Eyepoint Pharmaceuticals by 22.6% during the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after acquiring an additional 663,439 shares in the last quarter. Aberdeen Group plc increased its holdings in shares of Eyepoint Pharmaceuticals by 52.0% during the third quarter. Aberdeen Group plc now owns 3,053,945 shares of the company’s stock valued at $9,986,000 after acquiring an additional 1,045,143 shares in the last quarter. Commodore Capital LP bought a new stake in shares of Eyepoint Pharmaceuticals in the first quarter worth approximately $36,414,000. Hsbc Holdings PLC bought a new stake in shares of Eyepoint Pharmaceuticals during the 1st quarter valued at $10,743,000. Finally, Stempoint Capital LP lifted its holdings in Eyepoint Pharmaceuticals by 129.1% in the 1st quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after purchasing an additional 456,915 shares in the last quarter. 99.41% of the stock is currently owned by institutional investors.
About Eyepoint Pharmaceuticals
EyePoint Pharmaceuticals is a biopharmaceutical company focused on developing treatments for serious eye diseases. Its drug-delivery technology is designed to provide sustained release of medication in the eye, with the goal of reducing the need for frequent injections or other repeated treatments. The company’s pipeline includes DURAVYU, an investigational sustained-release treatment being studied for retinal conditions including wet age-related macular degeneration and diabetic retinopathy. EyePoint previously developed and marketed ophthalmic products including YUTIQ and DEXYCU, and sold those commercial assets to Alimera Sciences in 2023.
Recommended Stories
- Five stocks we like better than Eyepoint Pharmaceuticals
- NVIDIA’s Turbulence Could Have Ripple Effects Across Quantum Computing
- Banking on AI: Can Upstart’s New Bank Plan Turn Its Stock Around?
- Amazon’s Black Friday Rush Could Kick Off a Holiday Season That Defines Its Year
- The Next Nuclear Opportunity May Be in Fuel, Not Reactors: 3 Stocks to Watch
Receive News & Ratings for Eyepoint Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eyepoint Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
